Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants-Reference-Cited by-同舟云学术

Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants

Published:2019-12-10 Issue:6 Volume:9 Page:677-688
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Gong Xiaohua¹,Darpo Borje²,Xue Hongqi²,Punwani Naresh¹,He Kevin³,Barbour April M.¹,Epstein Noam¹,Landman Robert¹,Chen Xuejun¹,Yeleswaram Swamy¹

Affiliation:

1. Incyte Research Institute Wilmington Delaware USA

2. eRT/iCardiac Technologies Rochester New York USA

3. Incyte Corporation Wilmington Delaware USA

Funder

Incyte Corporation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.758

Reference29 articles.

1. Human absorption, metabolism and elimination of itacitinib in healthy male adult volunteers;Boer J;Clin Pharmacol Drug Dev,2018

2. International Council for Harmonisation. E14 Guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhytmic drugs.2005.https://database.ich.org/sites/default/files/E14_Guideline.pdf. Accessed October 12 2019.

3. Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

4. ICH E14 Guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs;E14 Implementation Working Group;Questions & answers (R3),2015

5. Study Design Parameters Affecting Exposure Response Analysis of QT Data: Results From Simulation Studies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies;Pharmacology Research & Perspectives;2021-12-24

2. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward;Frontiers in Immunology;2021-10-28

3. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease;Biochemical Pharmacology;2020-08

4. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future;Biomolecules;2020-07-05

5. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA;Viruses;2020-05-10